Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women - Full Text View

Sponsors and Collaborators:	Laval University Canadian Institutes of Health Research (CIHR) Centre Hospitalier de l'Universite Laval (CHUL)
Information provided by:	Laval University
ClinicalTrials.gov Identifier:	NCT00136643

Purpose

The objectives of this clinical study are to evaluate the extended safety, tolerance and acceptability of a vaginal gel formulation when applied in 452 healthy women volunteers. This vaginal formulation was shown to be well tolerated in a previous smaller clinical study. The formulation is being developed as a microbicide for the prevention of sexually transmitted infections (STIs) including HIV.

Condition	Intervention	Phase
HIV Infections Sexually Transmitted Diseases	Drug: Invisible Condom®	Phase I Phase II

MedlinePlus related topics: AIDS Sexually Transmitted Diseases

Drug Information available for: Sodium dodecyl sulfate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study
Official Title:	A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance and Acceptability of a Vaginal Gel Containing Sodium Lauryl Sulfate (Invisible Condom®) in Healthy Female Subjects

Further study details as provided by Laval University:

Primary Outcome Measures:

Safety and tolerance outcomes: Subjective assessment; Objective assessment

Secondary Outcome Measures:

Acceptability assessment

Estimated Enrollment:	452
Study Start Date:	June 2005
Study Completion Date:	July 2007

Detailed Description:

Objectives: The objectives of this Phase I/II clinical trial are to evaluate the safety, tolerance and acceptability of a gel formulation containing sodium lauryl sulfate (SLS) (compared to gel alone and placebo) when applied intravaginally in healthy volunteers.

Design: In part A of the protocol, three groups: gel alone, gel plus SLS, and placebo will be tested for safety, tolerance and acceptability when applied intravaginally once, twice or three times daily for 14 days in 252 healthy subjects. The volunteers will be divided as follow: 36 sexually abstinent healthy subjects (12 per group) will apply the gel, gel plus SLS or the placebo once daily for 14 days; 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo once daily for 14 days; 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo twice daily for 14 days and 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo three times daily for 14 days. The gel will be applied between menses. For the sexually active group, the gel should be applied less than 1 hour before sexual intercourse, if planned. Subjects will have vaginal intercourse a minimum of 4 times in a 2-week period of gel application.

In part B of the protocol, the extended safety of the gel alone, gel plus SLS and placebo will be studied when applied intravaginally twice daily for 8 weeks in sexually active healthy subjects. In this part B (actually represents Phase II of the trial), 80 healthy sexually active subjects for the gel alone group and 80 subjects for the gel + SLS group and 40 subjects for the placebo group, will be studied. The part B involves the participation of a total of 200 subjects. Subjects will have vaginal intercourse a minimum of 4 times in a 2-week period of gel application. The gel will be applied between menses. The gel should be applied less than 1 hour before sexual intercourse, if planned, but no more than twice a day.

Eligibility

Ages Eligible for Study:	18 Years to 49 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Sign an informed consent
Healthy female subjects aged between 18 to 49. Healthy female subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination and laboratory tests.
Normal physical and gynecological examinations
Normal colposcopic examination
Have regular menstrual cycle with 21-40 days between menses
HIV-negative subjects and at low risk of acquiring HIV
At low risk of getting STIs (i.e. sexually abstinent or having history of protected sexual intercourse or having a stable sexual partner). Sexual intercourse is defined here as vaginal penetration. Stable sexual partner is defined as the same sexual partner for the length of the study.
Agreeing to abstain from sexual intercourse from screening to the end of the study (for sexually abstinent subjects).
Agreeing to have sexual intercourse a minimum of 4 times for each period of two weeks of gel application (for sexually active subjects)

Exclusion Criteria:

Clinically significant abnormal physical and/or gynecological examination
Clinically significant abnormal laboratory findings
Allergy to applicator material (polyethylene) or to gel polymer (polyoxyethylene-polyoxypropylene) or to latex
Participation in any investigational study involving drugs, vaccines or microbicides in the last 30 days
History of toxic shock syndrome
HIV infection
Bacterial vaginosis or Candida or Trichomonas vaginitis at time of screening
STIs (gonorrhea, chlamydia, syphilis, genital herpes, chancroid) at time of screening
Breakthrough menstrual bleeding, or vaginal bleeding during or following sexual intercourse, in the last 3 months
Intravenous (IV) drug use except for medical reasons in the last year
Pregnant at enrolment or breast-feeding
Having received antibiotics in the last 14 days
Subjects considered as unreliable or unable to understand or follow the study protocol directions
Use of an intrauterine device

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00136643

Locations

Cameroon
Laboratoire de Santé Hygiène Mobile
Yaoundé, Cameroon

Sponsors and Collaborators

Laval University

Canadian Institutes of Health Research (CIHR)

Centre Hospitalier de l'Universite Laval (CHUL)

Investigators

Principal Investigator:

Michel G. Bergeron, MD, FRCPC

Prof. and Director of Infectious Diseases Research Center, Laval University

More Information

Study ID Numbers:	CRI-INV.06, FRN: 67531
Study First Received:	August 26, 2005
Last Updated:	October 9, 2007
ClinicalTrials.gov Identifier:	NCT00136643
Health Authority:	Canada: Health Canada; United States: Food and Drug Administration; Cameroon: Ministry of Public Health

Keywords provided by Laval University:

microbicide
Women
Prevention
HIV

STIs
HIV Seronegativity
prevention of sexually transmitted infections including HIV.

Study placed in the following topic categories:

Genital Diseases, Female
Virus Diseases
Sexually Transmitted Diseases, Viral
HIV Infections
Acquired Immunodeficiency Syndrome

Sexually Transmitted Diseases
Healthy
Genital Diseases, Male
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
Lentivirus Infections
Infection

ClinicalTrials.gov processed this record on January 16, 2009